374 related articles for article (PubMed ID: 19918119)
21. Staging disease severity in movement disorder tauopathies: brain atrophy separates progressive supranuclear palsy from corticobasal degeneration.
Schofield EC; Caine D; Kril JJ; Cordato NJ; Halliday GM
Mov Disord; 2005 Jan; 20(1):34-9. PubMed ID: 15390131
[TBL] [Abstract][Full Text] [Related]
22. Quantitative assessment of subcortical atrophy and iron content in progressive supranuclear palsy and parkinsonian variant of multiple system atrophy.
Lee JH; Han YH; Kang BM; Mun CW; Lee SJ; Baik SK
J Neurol; 2013 Aug; 260(8):2094-101. PubMed ID: 23670309
[TBL] [Abstract][Full Text] [Related]
23. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration.
Gröschel K; Hauser TK; Luft A; Patronas N; Dichgans J; Litvan I; Schulz JB
Neuroimage; 2004 Feb; 21(2):714-24. PubMed ID: 14980574
[TBL] [Abstract][Full Text] [Related]
24. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
25. [Recent neuropathology of parkinsonian syndromes].
Duyckaerts C; Verny M; Hauw JJ
Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S11-8. PubMed ID: 12773883
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional changes in multiple system atrophy and Parkinson's disease putamen.
Vogt IR; Lees AJ; Evert BO; Klockgether T; Bonin M; Wüllner U
Exp Neurol; 2006 Jun; 199(2):465-78. PubMed ID: 16626704
[TBL] [Abstract][Full Text] [Related]
27. FBXO7 immunoreactivity in α-synuclein-containing inclusions in Parkinson disease and multiple system atrophy.
Zhao T; Severijnen LA; van der Weiden M; Zheng PP; Oostra BA; Hukema RK; Willemsen R; Kros JM; Bonifati V
J Neuropathol Exp Neurol; 2013 Jun; 72(6):482-8. PubMed ID: 23656991
[TBL] [Abstract][Full Text] [Related]
28. Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration.
Fabbrini G; Fabbrini A; Suppa A
Handb Clin Neurol; 2019; 165():155-177. PubMed ID: 31727210
[TBL] [Abstract][Full Text] [Related]
29. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
[TBL] [Abstract][Full Text] [Related]
30. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process.
Togo T; Dickson DW
Acta Neuropathol; 2002 Oct; 104(4):398-402. PubMed ID: 12200627
[TBL] [Abstract][Full Text] [Related]
31. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
Paviour DC; Thornton JS; Lees AJ; Jäger HR
Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
[TBL] [Abstract][Full Text] [Related]
32. Discriminating among degenerative parkinsonisms using advanced (123)I-ioflupane SPECT analyses.
Badoud S; Van De Ville D; Nicastro N; Garibotto V; Burkhard PR; Haller S
Neuroimage Clin; 2016; 12():234-40. PubMed ID: 27489771
[TBL] [Abstract][Full Text] [Related]
33. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
[TBL] [Abstract][Full Text] [Related]
34. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
Fitzmaurice PS; Ang L; Guttman M; Rajput AH; Furukawa Y; Kish SJ
Mov Disord; 2003 Sep; 18(9):969-76. PubMed ID: 14502663
[TBL] [Abstract][Full Text] [Related]
35. Sporadic four-repeat tauopathy with frontotemporal lobar degeneration, Parkinsonism, and motor neuron disease: a distinct clinicopathological and biochemical disease entity.
Fu YJ; Nishihira Y; Kuroda S; Toyoshima Y; Ishihara T; Shinozaki M; Miyashita A; Piao YS; Tan CF; Tani T; Koike R; Iwanaga K; Tsujihata M; Onodera O; Kuwano R; Nishizawa M; Kakita A; Ikeuchi T; Takahashi H
Acta Neuropathol; 2010 Jul; 120(1):21-32. PubMed ID: 20140439
[TBL] [Abstract][Full Text] [Related]
36. Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
Wolters A; Classen J; Kunesch E; Grossmann A; Benecke R
Mov Disord; 2004 May; 19(5):518-28. PubMed ID: 15133815
[TBL] [Abstract][Full Text] [Related]
37. [Neuroprotection and neurodegenerative parkinsonian syndromes].
Destée A
Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S93-104. PubMed ID: 12773894
[TBL] [Abstract][Full Text] [Related]
38. Neuropathologic Validation and Diagnostic Accuracy of Presynaptic Dopaminergic Imaging in the Diagnosis of Parkinsonism.
Hastings A; Cullinane P; Wrigley S; Revesz T; Morris HR; Dickson JC; Jaunmuktane Z; Warner TT; De Pablo-Fernández E
Neurology; 2024 Jun; 102(11):e209453. PubMed ID: 38759132
[TBL] [Abstract][Full Text] [Related]
39. Concomitant progressive supranuclear palsy and multiple system atrophy: more than a simple twist of fate?
Silveira-Moriyama L; González AM; O'Sullivan SS; Williams DR; Massey L; Parkkinen L; Ahmed Z; de Silva R; Chacón JR; Revesz T; Lees AJ; Holton JL
Neurosci Lett; 2009 Dec; 467(3):208-11. PubMed ID: 19835934
[TBL] [Abstract][Full Text] [Related]
40. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
